Cycling slows Parkinson disease progression
- Trial ID
- NCT06442033
- Official Title
- Genetics and Aerobic Exercise to Slow Parkinson's Disease (GEARS) Trial
- Goal
- Cycling slows Parkinson disease progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Jay Alberts
- Study Type
- INTERVENTIONAL
- Enrollment
- 200 participants
- Conditions
- Parkinson Disease
- Interventions
- High intensity stationary cycling
Plain-Language Summary
GEARS is testing whether high-intensity aerobic exercise, analyzed alongside participants' genetic information, can slow Parkinson's progression and improve motor function. The plan uses supervised high-intensity stationary cycling to raise heart rate and boost brain-protective growth factors like BDNF, which may strengthen motor circuits and slow neurodegeneration; exercise is used alongside, not instead of, usual medicines and participants stay on a stable anti-parkinsonian regimen. The trial is looking for adults 18 and older with Parkinson's at Hoehn and Yahr stages 1 to 3 who can safely mount a stationary bike, have reliable transportation and a smartphone for activity tracking, and are on stable medication. People with dementia, implanted DBS or focused ultrasound, certain heart or musculoskeletal problems, other neurological diseases, or current participation in another disease-modifying PD trial are not eligible, and anyone flagged by the ACSM screen must get medical clearance first.
Locations
- The Cleveland Clinic, Cleveland, Ohio, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying High intensity stationary cycling. GEARS is testing whether high-intensity aerobic exercise, analyzed alongside participants' genetic information, can slow Parkinson's progression and improve motor function. The plan uses supervised high-intensity stationary cycling to raise heart rate and boost brain-protective growth factors like BDNF, which may strengthen motor circuits and slow neurodegeneration; exercise is used alongside, not instead of, usual medicines and participants stay on a stable anti-parkinsonian regimen. The trial is looking for adults 18 and older with Parkinson's at Hoehn and Yahr stages 1 to 3 who can safely mount a stationary bike, have reliable transportation and a smartphone for activity tracking, and are on stable medication. People with dementia, implanted DBS or focused ultrasound, certain heart or musculoskeletal problems, other neurological diseases, or current participation in another disease-modifying PD trial are not eligible, and anyone flagged by the ACSM screen must get medical clearance first.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 4 months.